The Indian pharmaceutical sector showed mixed performance as of February 1, 2026, around 10 AM IST, with many stocks trading in negative territory amid cautious market sentiment ahead of the Union Budget 2026. The broader market indices were volatile, with the Nifty 50 near 25,300-25,320 levels (flat to slightly down) and the Sensex around 82,300 (marginally up or flat in early trade).
The provided data lists BSE and NSE prices with percentage changes for various pharma scrips at approximately 10 AM. Most stocks recorded minor declines, though some showed gains.
Key Observations from the Data (as of ~10 AM IST, Feb 1, 2026):
- Top Gainers:
- Shilpa Medicare: +9.73% on BSE (318.15 Rs), +7.63% on NSE (311.00 Rs).
- Suven Life Sciences: +2.33% on BSE (135.90 Rs).
- Indraprastha Medical: +2.11% on BSE (371.00 Rs).
- Sun Pharma: +1.76% on BSE (1,623.10 Rs), +1.86% on NSE (1,625.00 Rs).
- Dishman Carbogen Amcis: +1.63% on BSE (221.75 Rs).
- Notable Decliners:
- Jubilant Industries: -4.08% on BSE (1,639.05 Rs).
- Advanced Enzyme Technologies: -3.56% on BSE (286.00 Rs).
- Alivus Life Sciences: -2.76% on BSE (934.90 Rs).
- Aurobindo Pharma: -2.21% on BSE (1,185.50 Rs).
- Several mid- and large-cap names like Glenmark Pharma (-1.67% to -1.85%), Granules India (-1.47%), and IPCA Labs (-1.19% to -1.48%) traded lower.
- Major Large-Cap Pharma Stocks:
- Sun Pharma: Up around 1.76-1.86%, supported by recent positive Q3 FY26 results (16% YoY profit growth reported earlier).
- Divi’s Laboratories: Minor dip (-0.20% to -0.05%).
- Cipla: Slight decline (-0.26% to -0.23%).
- Dr. Reddy’s Labs: Nearly flat (-0.04% to -0.02%).
- Torrent Pharma: Minor decline (-0.35% to -0.38%).
- Abbott India: Down -0.88% to -0.51%.
- Other Notes:
- Many stocks showed declines of 0.5-2%, reflecting sector caution.
- Some like Alembic (+0.08% to +0.05%), Concord Biotech (+0.60% to +0.43%), and Marksans Pharma (+0.34% to +0.79%) held positive or flat.
- The Nifty Pharma index (from recent references) was around 21,700-21,730 levels earlier in the session, with minor positive bias in some reports, though individual stocks varied.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
